Cartography of SARS-CoV-2 variants based on the susceptibility to therapeutic monoclonal antibodies

Yuki Furuse

doi:10.1002/jmv.28275

Cartography of SARS-CoV-2 variants based on the susceptibility to therapeutic monoclonal antibodies

J Med Virol. 2023 Jan;95(1):e28275. doi: 10.1002/jmv.28275. Epub 2022 Nov 10.

Author

Yuki Furuse^{1

2

3

4}

Affiliations

¹ Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
² Medical Education Development Center, Nagasaki University Hospital, Nagasaki, Japan.
³ Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
⁴ Hakubi Center for Advanced Research, Kyoto University, Kyoto, Japan.

Abstract

A comprehensive picture of a phenotypic relationship among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has been poorly studied. Here, this study presents cartography showing how the wild-type strain of SARS-CoV-2 and 14 variants are alike or different from the perspective of the susceptibility to 12 therapeutic monoclonal antibodies. The Alpha variant is close to the wild-type strain, whereas the Beta, Gamma, and Delta variants diverge from the wild-type. The map highlights the very unique property of the Omicron variant. Interestingly, sublineages of the Omicron variants, BA.1, BA.2, and BA.4/5, differ substantially in the cartography.

Keywords: COVID-19; SARS-CoV-2; antibody; evolution; neutralization; variant.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Neutralizing
Antibodies, Viral / therapeutic use
COVID-19*
Humans
SARS-CoV-2* / genetics
Spike Glycoprotein, Coronavirus / genetics

Substances

Antibodies, Monoclonal
Antibodies, Neutralizing
Antibodies, Viral
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2

Supplementary concepts

SARS-CoV-2 variants